Bright Technologies Fund Invests in APR Applied Pharma Research SA

Balerna, June 06, 2012

Bright Technologies Fund invests an undisclosed amount in APR Applied Pharma Research SA (“APR”), supporting the innovative Swiss life science sector. The fund’s advisor, Enrico Braglia, will become a member of the Board of Directors of APR.

“We are pleased to invest in APR. This investment underlines our commitment to Swiss life science, a sector with incredible growth potential”, said Enrico Braglia, CEO at Onelife Advisors SA advisor to Bright Technologies Fund. The fund aligns its investment in high-tech companies with significant market potential and supports start-up from beginning.

“The investment of Bright Technology Fund into APR is part of our overall strategic plan for the growth, which foresees the expansion of the firm’s geographic presence into the fast-growing markets as well as the acceleration of our development programs. Among recent accomplishments, we entered in a licensing partnership with Norgine BV for the EU and selected non-EU markets. We expanded into Latin America and Russia, where we have signed License and Supply Agreements with undisclosed leading pharmaceutical companies. We also expect to finalize our partnering efforts in China, shortly“, said APR CEO and founder Paolo Galfetti „I am excited about the opportunity to work with Enrico Braglia who will bring to APR his extensive expertise and network in the pharmaceutical industry.”

About APR
APR is an independent, international and integrated Healthcare Company headquartered in Switzerland and focused on three major areas: Delivering, Funding and Supporting Innovation in Healthcare. In particular, APR develops and licenses innovative, value added and patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early stage innovative projects and provides a balanced mix of equity funding and/or financing together with APR’s development, scientific, technical, marketing, licensing and management skills and know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basis added value, consultancy and R&D services under contract using a General Contractor approach. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 100 countries worldwide with international sales on a worldwide basis.

Onelife is a strategic advisory company based in Lugano. Onelife provides public and private equity financing through its investment funds: Prospera Senectute Fund (Sicaf-Sif), a life science dedicated fund that focus on healthy aging and Bright Technologies Fund, a private equity fund investing in innovative hi-tech companies with large market potential. Onelife also offers advices to financial institutions, companies and family offices with respect to their ventures in life science and high-technology.

2015-01-04T13:09:46+00:00 Applied Pharma Research (APR)